Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CDMO Avid Bioservices, Inc.

停牌 02-04 16:00:00 EST

12.49

+0.00

0.00%

最高12.49	最低12.49	成交量0.00
今开12.49	昨收12.49	日振幅0.00%
总市值7.99亿	流通市值6.32亿	总股本6,396万
成交额3,832万	换手率0.00%	流通股本5,062万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CDMO","market":"US","secType":"STK","nameCN":"Avid Bioservices, Inc.","latestPrice":12.49,"timestamp":1738702800000,"preClose":12.49,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":50623090,"shares":63963302,"eps":-2.394638,"marketStatus":"停牌","change":0,"latestTime":"02-04 16:00:00 EST","open":12.49,"high":12.49,"low":12.49,"amount":38318611.149448,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.394638,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.49,"volumeRatio":0},"requestUrl":"/m/hq/s/CDMO","defaultTab":"news","newsList":[{"id":"2633543917","title":"CDMO龙头三星生物罢工：中国CDMO企业迎订单转移窗口期？","url":"https://stock-news.laohu8.com/highlight/detail?id=2633543917","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633543917?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:23","pubTimestamp":1778232180,"startTime":"0","endTime":"0","summary":"【CDMO龙头三星生物罢工：中国CDMO企业迎订单转移窗口期？】全球生物医药合同研发生产组织（CDMO）行业的“定海神针”正面临成立以来的最大运营危机。根据公开信息，2026年5月1日起，全球生物药CDMO产能排名第一的韩国三星生物爆发全面罢工，这也是该公司自2011年成立以来的首次全线停工。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083731575828.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605083731575828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["EMXC","BK4585","BK4588","CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631686139","title":"康龙化成：小分子CDMO一季度订单加速增长来自两方面因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2631686139","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631686139?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:30","pubTimestamp":1777537800,"startTime":"0","endTime":"0","summary":"证券日报网4月30日讯，康龙化成在接受调研者提问时表示，小分子CDMO一季度订单加速增长来自两方面因素，分别是项目数量增加、项目进入中后期后带来的订单金额提升，其中FollowMolecule项目从早期进入后期带来的订单额放大是核心的贡献因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604303726489341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03759","BK0216","BK1141","CDMO","BK1576","BK4139","300759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630360531","title":"诚达药业2025年营收4.06亿元增21.99%，CDMO成第一大收入来源，扣非净利仍亏2669.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630360531","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630360531?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:11","pubTimestamp":1777284689,"startTime":"0","endTime":"0","summary":"数据显示，公司2025年实现营业收入4.06亿元，同比增长21.99%；归母净利润为-1192.58万元，同比增加57.56%；扣非净利润为-2669.29万元，同比增加53.72%。CDMO产品收入占比升至40.60%，首次成为第一大收入来源；左旋肉碱系列产品收入占比为58.73%，退居第二。2025年第四季度单季营业收入为1.21亿元；归母净利润为-2869.91万元；扣非净利润为-3059.55万元，当季扣非净利润亏损额高于全年累计值，表明全年经营性减亏成果未能延续至年末，Q4盈利压力明显加大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1777283201647343535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["301201","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364329","title":"高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630364329?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:25","pubTimestamp":1777281907,"startTime":"0","endTime":"0","summary":"股份方面，该行对评级为“买入”的股份持更正面态度，包括药明康德 、凯莱英 、微创机器人 及精锋医疗 。另外，该行将爱康医疗 评级升至“买入”，反映其执行力重启、利润率改善及中期能见度更清晰，并将微泰医疗 升级至“中性”，因国内竞争影响优于预期，且有序达成2026年指引。前者受累于持续的VBP相关利润压力及短期增长乏力，后者收入加速回升但仍不明朗，上行空间有限。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1141","603259","BK1100","BK0239","BK0216","BK1222","CDMO","LU2045819591.USD","LU0320764599.SGD","LU0348766576.USD","LU1934453819.USD","LU1997245094.SGD","06821","LU0348767384.USD","BK1617","LU0287142896.SGD","LU0456842615.SGD","BK1191","BK4139","LU0052750758.USD","LU1997245177.USD","LU0173614495.USD","BK1583","LU2242644610.SGD","LU2328871848.SGD","LU1328615791.USD","LU1808992512.USD","02359","BK1585","LU2125910500.SGD","BK1576","BK0132","02252","01066","02675","LU1046422090.SGD","LU2495084118.USD","LU1979443071.USD","LU0708995583.HKD","LU2488822045.USD","002821","LU1997244956.HKD","01789","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630325361","title":"褪去新冠商业化红利反而更强了！药明康德(02359)小分子CDMO单季度收入飙至69.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630325361","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630325361?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:17","pubTimestamp":1777281471,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日晚间，药明康德发布了其首季度财报，核心业务增长动能强劲。此次小分子CDMO业务单季收入逼近70亿元大关，具有非凡的里程碑意义。数据显示，截至一季度末，药明康德小分子CDMO管线总数已达3550个。此次小分子CDMO业务在“后新冠时代”创下收入新高，是药明康德从“事件驱动”增长全面转向“平台驱动”持续高增长的有力证明，也为其在全球医药产业链中的核心枢纽地位再添坚实注脚。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1934453819.USD","BK1141","BK1583","LU1969619763.USD","LU0320764599.SGD","LU0052750758.USD","LU1997245094.SGD","LU0348767384.USD","LU2328871848.SGD","LU0456842615.SGD","LU2488822045.USD","LU1997244956.HKD","LU1979443071.USD","BK4139","LU1997245177.USD","LU2045819591.USD","LU0348766576.USD","LU2242644610.SGD","603259","BK0216","BK1576","LU0708995583.HKD","CDMO","02359","LU1808992512.USD","LU2125910500.SGD","LU1046422090.SGD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630635623","title":"港股异动 | 凯莱英(06821)尾盘涨超5% 20亿元化学大分子CDMO项目落地天津 TIDES持续扩能扩产","url":"https://stock-news.laohu8.com/highlight/detail?id=2630635623","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630635623?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:41","pubTimestamp":1777275714,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英(06821)尾盘涨超5%，截至发稿，涨5.13%，报104.5港元，成交额1.18亿港元。消息面上，凯莱英化学大分子CDMO项目落地天津经开区。该项目将进一步提升公司在多肽、寡核苷酸（TIDES）等新分子类型的CDMO一站式服务能力，更好满足全球合作伙伴的多元需求。浙商证券此前指出，考虑到凯莱英小分子CDMO不错的在手PPQ项目，我们认为小分子CDMO业务仍具有较强的成长性。新兴业务板块多肽、寡核苷酸、ADC相关CDMO、制剂CDMO等仍有较大的成长空间和业绩弹性，","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK4588","LU1328615791.USD","002821","BK1191","BK0239","BK4585","VXUS","CDMO","BK4139","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629974938","title":"港股异动 | 凯莱英(06821)午后涨近6% 20亿元化学大分子创新药CDMO项目落地天津经开区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629974938","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629974938?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:26","pubTimestamp":1777011981,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英午后涨近6%，截至发稿，涨5.49%，报97.1港元，成交额4458.26万港元。公开数据显示，2025年凯莱英化学大分子CDMO板块实现营业收入10.28亿元，同比增长123.72%，成为公司增长最为迅速的业务单元。公司预计26年多肽PPQ项目将达4个且多肽固相合成产能将从25年底的4.5万升增至26年底的6.9万升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK0132","BK1574","VXUS","159992","LU1328615791.USD","BK0239","BK4588","002821","06821","BK4139","BK1191","CDMO","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624526715","title":"【机构调研精选】这家CRO公司年初至今新签订单保持增长势头，小分子CDMO服务毛利率有望提高！","url":"https://stock-news.laohu8.com/highlight/detail?id=2624526715","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624526715?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:40","pubTimestamp":1775094000,"startTime":"0","endTime":"0","summary":"人民财讯4月2日电，康龙化成(300759)3月31日召开电话会议，摩根士丹利、高盛证券、花旗证券、人保养老、新华资产、泰康资产、博时基金等180余家机构参会。康龙化成在电话会议中表示，2025年，公司新签订单金额同比增长超过14%。过去的一年，公司CDMO业务，在商业化生产方面取得了积极的进展。公司位于宁波和绍兴的原料药生产车间，历史性地通过了FDA批准前现场检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693041060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624299599","title":"康龙化成：制剂商业化车间投产获国际大药企订单 小分子CDMO毛利率有望提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2624299599","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624299599?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:16","pubTimestamp":1775034962,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月1日，康龙化成(300759.SZ)发布投资者关系活动记录表公告，公司位于北京第二园区的制剂商业化生产车间建设完成，并于2026年第一季度与一家国际大型制药公司签订战略合作协议，为其首个注册申报的口服小分子GLP-1受体激动剂提供商业化生产服务。报告期内，公司新签订单金额同比增长超过14%，新增客户超过950家，活跃客户超过3,300家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013691983183.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013691983183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDMO","BK0216","BK4139","BK1576","03759","BK1141","300759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620425493","title":"东曜药业-B(01875)发布年度业绩，收益7.48亿元 战略转型CDMO成果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425493","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620425493?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:03","pubTimestamp":1773842603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 发布截至2025年12月31日止年度业绩，该集团取得收益人民币7.48亿元，同比减少31.93%;研发开支8567.5万元，同比增加8.02%;公司权益持有人应占亏损约1亿元，每股亏损0.14元。公告称，产品销售收入为4.88亿元，同比下降44%，此变化主要系市场竞争加剧。CDMO业务收入为2.35亿元，同比增长13%。全年新增项目60个，项目总数累计至213个，其中ADC相关项目占比达68%。已签约未完成订单达3.08亿元，同比增长61%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","CDMO","BK1161","BK4139","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619157052","title":"美国OTC市场Scorpius Holdings, Inc.盘中异动 早盘股价大涨25.00%报0.015美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619157052","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619157052?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:03","pubTimestamp":1773324181,"startTime":"0","endTime":"0","summary":"北京时间2026年03月12日22时03分，美国OTC市场Scorpius Holdings, Inc.股票出现波动，股价快速上涨25.00%。截至发稿，该股报0.015美元/股，成交量382股，换手率0.00%，振幅24.17%。美国OTC市场Scorpius Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.75%。美国OTC市场Scorpius Holdings, Inc.公司简介：Scorpius Holdings Inc 是一家综合合同开发和制造组织 ，专注于将生物和细胞治疗项目快速推进到临床及其他领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312220301a4643d9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312220301a4643d9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDMO","BK4139","SCPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618259096","title":"新华制药：公司构建创新药+特色原料药+高端制剂+CDMO立体布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2618259096","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618259096?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:10","pubTimestamp":1773058240,"startTime":"0","endTime":"0","summary":"证券日报网讯3月9日，新华制药在互动平台回答投资者提问时表示，公司以大研发+全产业链+国际化为核心，构建创新药+特色原料药+高端制剂+CDMO的立体布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666266727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","06978","000756","CDMO","BK0164","159992","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613748599","title":"美国OTC市场Scorpius Holdings, Inc.盘中异动 下午盘快速上涨72.41%报0.010美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613748599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613748599?lang=zh_cn&edition=full","pubTime":"2026-02-24 03:17","pubTimestamp":1771874221,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日03时17分，美国OTC市场Scorpius Holdings, Inc.股票出现波动，股价快速上涨72.41%。截至发稿，该股报0.010美元/股，成交量833股，换手率0.00%，振幅72.41%。美国OTC市场Scorpius Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.43%。美国OTC市场Scorpius Holdings, Inc.公司简介：Scorpius Holdings Inc 是一家综合合同开发和制造组织 ，专注于将生物和细胞治疗项目快速推进到临床及其他领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224031701a716badc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224031701a716badc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDMO","SCPX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610568695","title":"高盛：今年内地医疗板块更依赖数据及盈利能见度 看好CDMO企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2610568695","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610568695?lang=zh_cn&edition=full","pubTime":"2026-02-09 14:08","pubTimestamp":1770617323,"startTime":"0","endTime":"0","summary":"今年要获得超越行业的回报，更依赖于关键数据公布、实际成交，以及盈利兑现或转折点的能见度。该行对医疗器械板块维持中性看法，虽然行业已触底，但需时逐步复苏；推荐买时代天使及威高股份。医疗服务板块方面，该行仍持相对谨慎态度，因成本控制措施的持续影响，以及疲弱的消费周期；下调海吉亚医疗评级至“中性”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","LU2488822045.USD","LU2242644610.SGD","BK1191","LU0320764599.SGD","HK0000306685.HKD","LU0196878994.USD","HK0000165453.HKD","LU2125910500.SGD","02359","LU2045819591.USD","HK0000320264.USD","LU1046422090.SGD","CDMO","SG9999014674.SGD","HK0000320223.HKD","LU0052750758.USD","LU0708995583.HKD","03692","159891","BK1576","BK1141","BK1589","06990","HK0000306701.USD","02268","BK1583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607049601","title":"外资CDMO纷纷易手，它们在华消失殆尽了 | 海斌访谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049601","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607049601?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:58","pubTimestamp":1769781533,"startTime":"0","endTime":"0","summary":"“不光是在收缩，是在消失。”澳斯康创始人罗顺近期接受第一财经记者采访时，这样评价跨国CDMO在华业务。CDMO是指合同研发和生产组织，它是制药产业链分工日益专业化的结果。2020年左右，一大批知名跨国企业如龙沙、赛默飞世尔、默克等都在中国投资了CDMO业务，并对中国业务寄予厚望。现在，潮水已经退去。目前，还在中国开展CDMO业务的跨国企业几乎只有德国的勃林格殷格翰了。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601303637350971.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637350971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603991833","title":"515亿温州富豪，28亿吞并苏州药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2603991833","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603991833?lang=zh_cn&edition=full","pubTime":"2026-01-16 21:42","pubTimestamp":1768570978,"startTime":"0","endTime":"0","summary":"温州医药首富李革，拿下一家同行。1月14日晚，他实控的药明合联，宣布将以现金要约方式，以31亿港元的估值，约合28亿人民币，控股东曜药业。李革的药明系较为慷慨，出价4港元/股，相较12月下旬2港元左右的股价，刚好溢价一倍，考虑部分购股权注销价为1.7665港元，其要约最高代价约27.9亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163622167671.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622167671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456846285.SGD","LU0823426308.USD","BK1610","LU0456827905.SGD","LU1688375341.USD","LU0307460666.USD","LU0359201612.USD","LU0979878070.USD","LU0588546209.SGD","LU0516422952.EUR","BK4139","LU0708995583.HKD","BK1589","02268","LU0572944931.SGD","BK1141","LU0039217434.USD","LU0417516902.SGD","LU0359202008.SGD","LU0516423091.SGD","LU3063872942.SGD","IE00B0JY6N72.USD","LU0326950275.SGD","LU0516422440.USD","LU0348735423.USD","CDMO","LU1720050803.USD","LU2488822045.USD","LU0140636845.USD","02269","BK1521","LU0516423174.USD","LU0181495838.USD","LU0327786744.USD","LU0051755006.USD","LU0823426480.USD","LU1242518931.SGD","LU1794554557.SGD","LU2039709279.SGD","LU0856984785.SGD","LU0052750758.USD","LU0516422366.SGD","SG9999002463.SGD","SG9999014674.SGD","LU0417516738.SGD","LU1242518857.USD","LU0043850808.USD","BK1576","SG9999002562.SGD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603610556","title":"业绩盈喜, 控股收购东曜药业，药明合联(02268)进一步稳固ADC CDMO市场地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2603610556","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603610556?lang=zh_cn&edition=full","pubTime":"2026-01-14 23:32","pubTimestamp":1768404738,"startTime":"0","endTime":"0","summary":"同时，通过此次控股收购，药明合联亦希望进一步丰富其项目组合并扩大其客户群，稳固其在 ADC CDMO 领域的领导地位。药明合联早已布局人才梯队建设，截至2025年底，团队规模已突破2600人。截至2025年12月底，药明合联在全球合作客户数量已超过630家，iCMC项目总数达到252个。这一举措不仅能实现产能的本地化交付，更能进一步深化公司在全球生物偶联药CDMO领域的市场覆盖，巩固行业领先地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","BK4080","CDMO","LU2488822045.USD","02268","BK4231","BK4139","ADC","BK1141"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2603664448","title":"里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业","url":"https://stock-news.laohu8.com/highlight/detail?id=2603664448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603664448?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:20","pubTimestamp":1768371626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，展望2026年，相信对中国医疗板块而言，盈利交付将比估值扩张更为重要，料药明康德 有望跑赢同业。该行将药明康德列为中国CRO/CDMO行业的首选。该行维持药明康德“跑赢大市”评级及目标价143.4港元。相较同行，药明康德具备更强的盈利增长可见性：其2025年前三季度订单储备同比增长41%，远高于全球平均约14%，即使在地缘政治风险持续的背景下仍保持强劲增势。该行预计2026年药明康德的订单增速将继续领先全球同行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","LU1997245094.SGD","LU1979443071.USD","600056","LU0456842615.SGD","603259","02359","BK0250","BK1576","CDMO","BK0216","LU1997244956.HKD","LU2242644610.SGD","BK1583","BK0188","BK0028","BK1141","BK0185","LU0052750758.USD","BK0175","LU1934453819.USD","LU1969619763.USD","LU1808992512.USD","LU2045819591.USD","LU2328871848.SGD","LU2488822045.USD","BK4139","LU1046422090.SGD","LU2125910500.SGD","BK0010","LU2495084118.USD","LU1997245177.USD","LU0708995583.HKD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603769682","title":"雅本化学：公司与恒瑞医药的合作模式为CDMO模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769682","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769682?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:38","pubTimestamp":1768311484,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，雅本化学在互动平台回答投资者提问时表示，公司与恒瑞医药的合作模式为CDMO模式，覆盖恒瑞医药从临床前到商业化生产的各个阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617688110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","LU1781817850.SGD","BK4139","LU2580892862.HKD","LU2543165471.USD","600276","BK0174","BK0183","LU0405327494.USD","LU1655091616.SGD","LU2097828631.EUR","LU2289578879.USD","LU1580142542.USD","LU0359201612.USD","LU2097828557.USD","LU1328615791.USD","LU2580892789.USD","LU1255011170.USD","BK0229","LU1146622755.USD","LU2488822045.USD","LU2097828805.USD","LU1997244956.HKD","LU1969619763.USD","BK0060","LU0405327148.USD","CDMO","BK0196","BK0028","LU1997245177.USD","300261","LU0359201885.HKD","LU2097828714.EUR","LU2148510915.USD","BK1191","LU2328871848.SGD","LU1064131003.USD","BK0012","BK0239","LU1820825898.SGD","LU2495084118.USD","LU0359202008.SGD","LU1997245094.SGD","LU2097828474.EUR","BK0188","LU1023057109.AUD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586020682","title":"乐普生物-B(02157)与乐普医疗订立CDMO服务框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2586020682","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586020682?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:48","pubTimestamp":1764319714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B(02157)发布公告，于2025年11月28日，本公司与乐普医疗订立CDMO服务框架协议，本公司及/或其附属公司同意向乐普医疗及/或其附属公司提供CDMO技术服务。考虑到本集团为满足自身临床试验及商业化而对药物生产的需求之外，本集团可在适当的商机出现时更有效利用富余产能。董事认为，订立CDMO服务框架协议将能更有效利用本集团的富余产能，可为本集团整体产生补充现金流量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0201","BK0114","300003","BK0028","BK1161","BK0251","BK0196","BK0188","02157","CDMO","BK4139","BK0042","BK0113"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avidbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avid Bioservices, Inc.最初于1981年6月在美国加州注册成立，并于1996年9月25日在美国特拉华州重新合并。该公司是一家专门的合同开发和制造组织（“CDMO”），提供从工艺开发到当前良好制造实践的全方位服务（“CGMP”）临床和商业制造，专注于从哺乳动物细胞培养中提取生物制药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.245054},{"month":2,"riseRate":0.580645,"avgChangeRate":0.056406},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.035156},{"month":4,"riseRate":0.4,"avgChangeRate":-0.032334},{"month":5,"riseRate":0.516129,"avgChangeRate":0.109027},{"month":6,"riseRate":0.419355,"avgChangeRate":0.007765},{"month":7,"riseRate":0.322581,"avgChangeRate":0.039463},{"month":8,"riseRate":0.354839,"avgChangeRate":0.002481},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.046446},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.040707},{"month":11,"riseRate":0.548387,"avgChangeRate":0.073378},{"month":12,"riseRate":0.419355,"avgChangeRate":0.023819}],"exchange":"NASDAQ","name":"Avid Bioservices, Inc.","nameEN":"Avid Bioservices, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avid Bioservices, Inc.,CDMO,Avid Bioservices, Inc.股票,Avid Bioservices, Inc.股票老虎,Avid Bioservices, Inc.股票老虎国际,Avid Bioservices, Inc.行情,Avid Bioservices, Inc.股票行情,Avid Bioservices, Inc.股价,Avid Bioservices, Inc.股市,Avid Bioservices, Inc.股票价格,Avid Bioservices, Inc.股票交易,Avid Bioservices, Inc.股票购买,Avid Bioservices, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}